Building trust in a complex global business
How COFCO International rebuilt trust under Chi Jingtao (Johnny) with alignment, values, and visible leadership....
Tech for Good
ESG
Bioversys: ‘Impact investors should focus more on equitable health’
With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of...
With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of Bioversys, which is developing new medicines for severe life-threatening bacterial infections that are resistant to antibiotics.
In episode five, Gitzinger says the biotech industry still focuses mainly on financial returns and calls on impact investors to pay more attention to the topic of equitable health to ensure access and proper control of good quality drugs throughout the world.
Gitzinger discusses how he defines success, including the importance of generating financial returns for the investors who have believed in the technology and backed the business.
Expert
Authors
More to explore
ShareFocus, bold bets, and a bit of fun: How a pharma chief is going for growth
Ipsen CEO David Loew tells Jean-François Manzoni how relentless focus, the Pareto principle, and having fun helped energize a mid-sized specialty pharma player to take on bigger rivals....
Rethinking sustainability: Why customer value comes first
A new book challenges the conventional belief that sustainability alone drives customer purchases. In a webinar hosted by Karl Schmedders, the book’s co-author, Goutam Challagalla, explains how companies can make sustainability...